Mercer Global Advisors
VRTX icon

Mercer Global Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Mercer Global Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3M Buy
30,705
+7,943
+35% +$3.52M 0.02% 442
2026
Q1 		$10.2M Sell
22,762
-1,060
-4% -$494K 0.02% 496
2025
Q4 		$8.99M Buy
23,822
+5,038
+27% +$2.17M 0.01% 521
2025
Q3 		$7.36M Buy
18,784
+261
+1% +$109K 0.01% 546
2025
Q2 		$8.25M Buy
18,523
+3,462
+23% +$1.6M 0.02% 437
2025
Q1 		$7.3M Buy
15,061
+1,053
+8% +$491K 0.02% 449
2024
Q4 		$5.64M Sell
14,008
-1,543
-10% -$715K 0.01% 512
2024
Q3 		$7.3M Sell
15,551
-952
-6% -$457K 0.02% 399
2024
Q2 		$7.7M Buy
16,503
+3,106
+23% +$1.35M 0.02% 358
2024
Q1 		$5.6M Sell
13,397
-1,119
-8% -$473K 0.02% 433
2023
Q4 		$5.91M Buy
14,516
+2,789
+24% +$1.03M 0.02% 421
2023
Q3 		$4.08M Buy
11,727
+713
+6% +$249K 0.02% 486
2023
Q2 		$3.88M Buy
11,014
+899
+9% +$303K 0.02% 519
2023
Q1 		$3.19M Buy
10,115
+1,821
+22% +$546K 0.01% 553
2022
Q4 		$2.4M Buy
8,294
+170
+2% +$51.8K 0.01% 648
2022
Q3 		$2.35M Sell
8,124
-835
-9% -$240K 0.01% 590
2022
Q2 		$2.52M Sell
8,959
-1,127
-11% -$302K 0.02% 552
2022
Q1 		$2.63M Buy
10,086
+613
+6% +$145K 0.02% 566
2021
Q4 		$2.08M Buy
9,473
+2,251
+31% +$438K 0.01% 608
2021
Q3 		$1.31M Buy
7,222
+814
+13% +$159K 0.01% 762
2021
Q2 		$1.29M Sell
6,408
-11,397
-64% -$2.38M 0.01% 735
2021
Q1 		$3.83M Buy
17,805
+12,652
+246% +$2.78M 0.03% 354
2020
Q4 		$1.22M Sell
5,153
-1,651
-24% -$379K 0.02% 551
2020
Q3 		$1.85M Buy
6,804
+687
+11% +$190K 0.03% 405
2020
Q2 		$1.78M Buy
6,117
+4,667
+322% +$1.27M 0.03% 352
2020
Q1 		$345K Sell
1,450
-47
-3% -$10.8K 0.01% 766
2019
Q4 		$328K Sell
1,497
-10
-0.7% -$2.02K 0.01% 882
2019
Q3 		$255K Buy
1,507
+49
+3% +$8.67K 0.01% 946
2019
Q2 		$267K Buy
1,458
+29
+2% +$5.07K 0.01% 923
2019
Q1 		$263K Buy
+1,429
New +$264K 0.01% 868

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Mercer Global Advisors's VRTX Position: Q2 2026 in Review

Mercer Global Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 35% in Q2 2026, buying an estimated $3.52M and bringing the position to 30,705 shares worth $15.3M. The position accounts for 0.02% of the portfolio, ranked #442.

Mercer Global Advisors first reported a position in VRTX in Q1 2019 and has held it in 30 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Mercer Global Advisors held 30,705 shares of Vertex Pharmaceuticals worth $15.3M as of Q2 2026.
  • Mercer Global Advisors bought 7,943 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.52M.
  • Vertex Pharmaceuticals made up 0.02% of Mercer Global Advisors's portfolio in Q2 2026, its #442 holding.
  • Mercer Global Advisors first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 30 quarters since.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.